Continuing Professional Development

Perioperative Bleeding Management


Seminar in Patient Blood Management - Focus on perioperative bleeding management

September 29 - October 03, 2017,   WEILL CORNELL MEDICINE - QATAR

Accreditation

logo-accreditation

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners - Accreditation Department and is approved for a maximum of 35.5 hours.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of  35.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Physicians

Overall Learning Objectives

  • Identify basic and special physiology and pathophysiology of hemostasis
  • Differentiate between diagnostic and therapeutic approaches
  • Identify preventive measures and management of drug effects 

Disclosure of Relationships/ContentValidity

It is the policy of Weill Cornell Medicine-Qatar to adhere to Qatar Council for Healthcare Practitioners (QCHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME activities are intended to be evidence-based and free of commercial bias.

Course Directors

Marcus D. Lance, MD, PhD; Robert Crone, MD
  • Have no relevant financial relationships to disclose
  • Will not be discussing any unlabeled/unapproved use of drugs or products

Planning Committee

Marcus D. Lance, MD, PhD; Robert Crone, MD; Prof. Marco Marcus, Deema Al Sheikhly, MRes, MEHP
    • Have no relevant financial relationships to disclose 
    • Will not be discussing any unlabeled/unapproved use of drugs or products

Presenters

Marcus Lance, MD, PhD; Gerhardus Kuiper, MD; Erik Beckers, MD; Yvonne Henskens, PhD; Marius Berger, MD; Mashael Al-Khelaifi, MD; Aysha Al-Maliki, MD; Ecaterina Scarlatescu, MD; Lidia Mora, MD; Blanca Martinez, MD; Seyed Tabatabaey,MD
  • Have no relevant financial relationships to disclose
  • Will not be discussing any unlabeled/unapproved use of drugs or products
Donat Spahn, MD, FRCA
  • Has disclosed the following: Advisor, Honorarium Recipient: Bayer(Slcheweiz)AG, Zürich,Switzerland, B. Braun Melsungen AG, Germany, Boehringer Ingelheim (Schewiz) GmbH, Basel Switzerland, CSL Behring GmbH Germany and Switzerland, Daiichi Sankyo Switzerland, Vifor AG Switzerland, Haemonetics Braintree MA USA, LFB Biomedicaments France, PAION Deutschland GmbH Germany, Pharmacosmos Denmark, Photonics Healthcare Netherlands, Roche Diagnostics International Ltd Switzerland, Sarstedt AG & Co Switzerland and Germany, Britstol -Myers-Squibb,Tem International GmbH Germany.
  •  Will be discussing the following products and services: Fibrinogen, Prothrimbin complex concentrate,  FXIII,  Iv Iron, Rivaroxaban, Apixaban,  Edoxaban,  Dabigatran, Idarumizumab, TEG, ROTEM, Multiplate,
Aamer Ahmed, BMedSci (hons) BMBS, DCH, FRCA, FESC, FACC 
  • Has disclosed the ff: Honorarium recipient for Lecture fees: Masimo
  • Will not be discussing any unlabelled/unapproved use of drugs or products
Seyed Tabatabaey, MD 
  • Has no relevant financial relationships to disclose
  • Will be discussing the following products: FVila, FXIII, Vasopresin

Course Coordinator

Dinnah Betonio
  • Has no relevant financial relationships to disclose
  • Will not be discussing any unlabeled/unapproved  use of drugs or products

CPD Staff

  • Have no relevant financial relationships to disclose
  • Will not be discussing any unlabeled/unapproved use of drugs or products

Industry Funding

The Weill Cornell Medicine-Qatar activity is funded in part by an unrestricted educational grant from CSL Behring.